)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
Karyopharm Therapeutics (KPTI) investor relations material
Karyopharm Therapeutics Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary11 Aug, 2025
Executive summary
Q2 2025 total revenue was $37.9M, with U.S. XPOVIO net product revenue up 6% year-over-year to $29.7M.
Net loss was $37.3M for Q2 2025; accumulated deficit reached $1.6B as of June 30, 2025.
Company is exploring financing and strategic alternatives to extend cash runway and maximize value.
Focus remains on advancing selinexor for myelofibrosis, endometrial cancer, and multiple myeloma, with top-line data from key Phase 3 trials expected in 2026.
Workforce reduced by approximately 20% in July 2025 to manage operating expenses.
Financial highlights
Q2 2025 total revenue was $37.9M, down from $42.8M in Q2 2024, mainly due to lower non-recurring license revenue.
U.S. XPOVIO net product revenue was $29.7M, up from $28M in Q2 2024; net product revenue grew 6% YoY.
Net loss was $37.3M ($4.32/share GAAP), compared to net income of $23.8M in Q2 2024, which included a $44.7M gain on extinguishment of debt.
Cash, cash equivalents, and investments were $52M as of June 30, 2025, down from $109.1M at year-end 2024.
Operating expenses for Q2 2025 were $62.3M, down 12% year-over-year, reflecting cost reduction initiatives.
Outlook and guidance
2025 total revenue guidance: $140M–$155M; U.S. XPOVIO net product revenue: $110M–$120M.
R&D and SG&A expenses expected at $240M–$250M for 2025.
Existing liquidity expected to fund operations through October 2025 note maturity and into January 2026, excluding note maturity and minimum liquidity covenant.
Net product revenue expected to increase in H2 2025 due to lower product returns, lower 340B discounts, and increased demand.
Top-line data from Phase 3 myelofibrosis trial expected March 2026; additional late-stage trial data expected in 2026.
What's the biggest worry about the MF readout?
How will protocol amendment help SENTRY-2 enrollment?
Discuss scenarios to enhance liquidity and value.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Karyopharm Therapeutics earnings date
Q3 20254 Nov, 2025
Next Karyopharm Therapeutics earnings date
Q3 20254 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
)
Edge19 Sep 2025
American Express: An Empire of Plastic
How history, brand, and structure have steadily built American Express' moat, and why Warren Buffett still calls it a one-of-a-kind business.
Frequently asked questions
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. Karyopharm Therapeutics develops therapeutic drug products based on an innovative drug delivery technology that has the potential to improve drug efficacy and safety in open label settings. Its lead product candidate, KPT-8602 for solid tumors and KPT-1203 for hematological malignancies, uses its proprietary Permeation Enhancing Sequence (PES)-based lipophilic doxorubicin (DOX) prodrug platform to develop novel therapeutics with potential clinical and commercial applications. Karyopharm Therapeutics is also developing KRN2300 to treat patients with multiple myeloma.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage